

March 31, 2026

Mochida Pharmaceutical Co., Ltd.
LG Chem, Ltd.

Announcement of a Partnership Agreement for Dinagest in South Korea and Thailand

Mochida Pharmaceutical Co., Ltd. (Head office: Shinjuku-ku, Tokyo, President: Naoyuki Mochida, hereinafter “Mochida”) and LG Chem, Ltd. (Head office: Seoul, South Korea, CEO: Kim Dong-choon, hereinafter “LG Chem”) announce that they have entered into a partnership agreement for Dinagest (hereinafter “the Product”), which is sold by Mochida in Japan and is indicated for endometriosis and other conditions.

Under this agreement, Mochida has granted LG Chem the exclusive rights to develop and market the Product in South Korea and Thailand. LG Chem will obtain the required marketing authorizations in each country and subsequently make the Product available to patients.

Mochida has been committed to providing products that support women’s health for more than 110 years since its founding. Mochida launched the Product in Japan in 2008 and has been exploring opportunities for its expansion into overseas markets. Furthermore, Mochida has been promoting its global expansion toward 2031, and as part of these efforts, Mochida is moving forward with the first global expansion of the Product through the conclusion of this agreement.

LG Chem is a leading global life sciences company representing South Korea, with more than 40 years of innovation since establishing the nation’s first genetic engineering research laboratory in 1981. Across a wide range of therapeutic areas, LG Chem has consistently developed and delivered innovative medicines that advance patient care. In the field of reproductive medicine, LG Chem has built over three decades of specialized expertise in the research and manufacturing of hormone-based therapies for infertility treatment. Through global-standard quality, ongoing R&D, and a strong commitment to patients and physicians, LG Chem continues to be a trusted partner in the field of reproductive medicine.

Mochida and LG Chem have previously entered into a partnership agreement regarding biosimilars of etanercept and adalimumab, which were subsequently launched in Japan. Under the newly concluded agreement, Mochida and LG Chem aim to deliver the Product to patients in South Korea and Thailand and contribute to improving their quality of life.

About Dinagest

Dienogest, the active ingredient in Dinagest, is a progestin that suppresses ovarian function and inhibits the proliferation of endometrial cells through its selective agonist activity for the progesterone receptor. In Japan, Mochida developed and launched Dinagest Tablets 1mg in 2008 as a treatment for endometriosis. Approval for an additional indication, the reduction of pain caused by adenomyosis, was obtained in 2016 for Dinagest Tablets 1mg. Furthermore, in 2020, Dinagest Tablets 0.5mg were launched as a treatment for dysmenorrhea. Dinagest continues to contribute to the treatment of conditions specific to women's health.

About Mochida

Mochida Pharmaceutical Co., Ltd. has been committed to research and development of innovative pharmaceutical products since its establishment in 1913 thus providing distinctive medicines to the medical community. Currently, the core pharmaceutical business focuses its resources on the targeted areas of cardiovascular medicine, gastroenterology, obstetrics and gynecology, and psychiatry while also providing medicines for intractable diseases and generics including biosimilars, to meet medical needs. For more information, please visit www.mochida.co.jp.

About LG Chem

LG Chem is a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, the life sciences business division of LG Chem, is dedicated to developing and delivering innovative medicines across a broad range of therapeutic areas. Guided by its mission to transform people's lives through inspiring science and leading innovation, LG Chem Life Sciences is offering differentiated solutions to its customers. For more information, please visit www.lgchem.com.

###

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
